New hope for kids with Tough-to-Treat leukemia
NCT ID NCT07437170
Summary
This study is testing whether adding the drug selinexor to standard chemotherapy works better for children with a specific high-risk type of acute myeloid leukemia (AML) called NUP98-fusion positive. It will involve 10 children to see if this combination leads to more patients achieving complete remission and becoming cancer-free. The main goal is to improve survival for these children who currently have poor outcomes with standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.